## Sean D Sullivan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10520587/publications.pdf

Version: 2024-02-01

109264 175177 12,115 53 35 52 citations h-index g-index papers 53 53 53 14131 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study. Lancet, The, 2007, 370, 741-750.	6.3	1,818
2	An Official American Thoracic Society/European Respiratory Society Statement: Asthma Control and Exacerbations. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 59-99.	2.5	1,591
3	Expenditures and Health Status Among Adults With Back and Neck Problems. JAMA - Journal of the American Medical Association, 2008, 299, 656.	3.8	1,291
4	Budget Impact Analysisâ€"Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value in Health, 2014, 17, 5-14.	0.1	742
5	Cost-Effectiveness Analysis Alongside Clinical Trials II—An ISPOR Good Research Practices Task Force Report. Value in Health, 2015, 18, 161-172.	0.1	539
6	Principles of Good Practice for Budget Impact Analysis: Report of the ISPOR Task Force on Good Research Practices—Budget Impact Analysis. Value in Health, 2007, 10, 336-347.	0.1	517
7	Efficacy of Antiseptic-Impregnated Central Venous Catheters in Preventing Catheter-Related Bloodstream Infection. JAMA - Journal of the American Medical Association, 1999, 281, 261.	3.8	514
8	The Economic Burden of COPD. Chest, 2000, 117, 5S-9S.	0.4	507
9	The health economics of asthma and rhinitis. I. Assessing the economic impact. Journal of Allergy and Clinical Immunology, 2001, 107, 3-8.	1.5	490
10	Global Epidemiology of Hepatitis B Virus. Journal of Clinical Gastroenterology, 2004, 38, S158-S168.	1.1	489
11	Daily versus As-Needed Corticosteroids for Mild Persistent Asthma. New England Journal of Medicine, 2005, 352, 1519-1528.	13.9	363
12	Key principles for the improved conduct of health technology assessments for resource allocation decisions. International Journal of Technology Assessment in Health Care, 2008, 24, 244-258.	0.2	356
13	Trends in the cost of illness for asthma in the United States, 1985-1994. Journal of Allergy and Clinical Immunology, 2000, 106, 493-499.	1.5	328
14	Rapid Magnetic Resonance Imaging vs Radiographs for Patients With Low Back Pain. JAMA - Journal of the American Medical Association, 2003, 289, 2810.	3.8	311
15	The Burden of Obstructive Lung Disease Initiative (BOLD): Rationale and Design. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2005, 2, 277-283.	0.7	256
16	Cost Effectiveness of Lung-Volume–Reduction Surgery for Patients with Severe Emphysema. New England Journal of Medicine, 2003, 348, 2092-2102.	13.9	218
17	The economic burden of asthma in US children: Estimates from the National Medical Expenditure Surveya~†a~†a~†a~ Journal of Allergy and Clinical Immunology, 1999, 104, 957-963.	1.5	182
18	Epidural Corticosteroid Injections for Radiculopathy and Spinal Stenosis. Annals of Internal Medicine, 2015, 163, 373-381.	2.0	146

#	Article	IF	Citations
19	EBM, HTA, and CER: Clearing the Confusion. Milbank Quarterly, 2010, 88, 256-276.	2.1	140
20	The cost-effectiveness of an inner-city asthma intervention for children. Journal of Allergy and Clinical Immunology, 2002, 110, 576-581.	1.5	129
21	On the use of survival analysis techniques to estimate medical care costs. Journal of Health Economics, 1999, 18, 365-380.	1.3	89
22	Asthma outcomes: Healthcare utilization and costs. Journal of Allergy and Clinical Immunology, 2012, 129, S49-S64.	1.5	88
23	Vascular Catheter Site Care: The Clinical and Economic Benefits of Chlorhexidine Gluconate Compared with Povidone Iodine. Clinical Infectious Diseases, 2003, 37, 764-771.	2.9	81
24	Cost-effectiveness analysis of early intervention with budesonide in mild persistent asthma. Journal of Allergy and Clinical Immunology, 2003, 112, 1229-1236.	1.5	69
25	A Multisite Randomized Trial of the Effects of Physician Education and Organizational Change in Chronic Asthma Care. JAMA Pediatrics, 2005, 159, 428.	3.6	62
26	Are Key Principles for improved health technology assessment supported and used by health technology assessment organizations?. International Journal of Technology Assessment in Health Care, 2010, 26, 71-78.	0.2	52
27	The utility of the Health Plan Employer Data and Information Set (HEDIS) asthma measure to predict asthma-related outcomes. Annals of Allergy, Asthma and Immunology, 2004, 93, 538-545.	0.5	50
28	Impact of asthma control on sleep, attendance at work, normal activities, and disease burden. Annals of Allergy, Asthma and Immunology, 2010, 105, 118-123.	0.5	49
29	Resource costs for asthma-related care among pediatric patients in managed care. Annals of Allergy, Asthma and Immunology, 2003, 91, 251-257.	0.5	46
30	Trends in cost and outcomes among adult and pediatric patients with asthma: 2000–2009. Annals of Allergy, Asthma and Immunology, 2013, 111, 516-522.	0.5	46
31	Study protocol: The back pain outcomes using longitudinal data (BOLD) registry. BMC Musculoskeletal Disorders, 2012, 13, 64.	0.8	45
32	Health economics of asthma and rhinitis. II. Assessing the value of interventions. Journal of Allergy and Clinical Immunology, 2001, 107, 203-210.	1.5	43
33	Cost Effectiveness of Entecavir versus Lamivudine with Adefovir Salvage in HBeAg-Positive Chronic Hepatitis B. Pharmacoeconomics, 2007, 25, 963-977.	1.7	42
34	Cost-Effectiveness Models for Chronic Obstructive Pulmonary Disease: Cross-Model Comparison of Hypothetical Treatment Scenarios. Value in Health, 2014, 17, 525-536.	0.1	41
35	Practice-Level Effects of Interventions to Improve Asthma Care in Primary Care Settings: The Pediatric Asthma Care Patient Outcomes Research Team. Health Services Research, 2005, 40, 1737-1757.	1.0	37
36	A Systematic Review to Assess Comparative Effectiveness Studies in Epidural Steroid Injections for Lumbar Spinal Stenosis and to Estimate Reimbursement Amounts. PM and R, 2013, 5, 705-714.	0.9	32

#	Article	IF	Citations
37	Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults. Dermatology and Therapy, 2017, 7, 493-505.	1.4	32
38	Cost-effectiveness of early intervention with once-daily budesonide in children with mild persistent asthma: results from the START study. Pediatric Allergy and Immunology, 2006, 17, 21-27.	1.1	31
39	Health technology assessment for resource allocation decisions: Are key principles relevant for Latin America?. International Journal of Technology Assessment in Health Care, 2010, 26, 421-427.	0.2	31
40	CAN WE RELIABLY BENCHMARK HEALTH TECHNOLOGY ASSESSMENT ORGANIZATIONS?. International Journal of Technology Assessment in Health Care, 2012, 28, 159-165.	0.2	30
41	Economic analysis of lung volume reduction surgery as part of the national emphysema treatment trial. Annals of Thoracic Surgery, 2001, 71, 995-1002.	0.7	28
42	Asthma in the United States: Recent Trends and Current Status. Journal of Managed Care Pharmacy, 2003, 9, 3-7.	2.2	28
43	Economic Evaluation in the US. Pharmacoeconomics, 2006, 24, 1163-1168.	1.7	27
44	Design and Analytic Considerations in Determining the Cost-Effectiveness of Early Intervention in Asthma from a Multinational Clinical Trial. Contemporary Clinical Trials, 2001, 22, 420-437.	2.0	23
45	Cost-effectiveness of peginterferon $\hat{l}$ ±-2a compared with lamivudine treatment in patients with HBe-antigen-positive chronic hepatitis B in the United Kingdom. European Journal of Gastroenterology and Hepatology, 2007, 19, 631-638.	0.8	18
46	The burden of uncontrolled asthma on the U.S. health care system. Managed Care, 2005, 14, 4-7; discussion 25-7.	0.3	16
47	Agreement between Caregiver Reported Healthcare Utilization and Administrative Data for Children with Asthma. Journal of Asthma, 2007, 44, 189-194.	0.9	15
48	Pharmacists as health care providers: Lessons from California and Washington. JACCP Journal of the American College of Clinical Pharmacy, 2018, 1, 39-44.	0.5	9
49	An epidemiologic model to project the impact of changes in glomerular filtration rate on quality of life and survival among persons with chronic kidney disease. International Journal of Nephrology and Renovascular Disease, 2014, 7, 271.	0.8	8
50	Toward a Hedonic Value Framework in Health Care. Value in Health, 2017, 20, 261-265.	0.1	8
51	Mapping a Patient-Reported Functional Outcome Measure to a Utility Measure for Comparative Effectiveness and Economic Evaluations in Older Adults with Low Back Pain. Medical Decision Making, 2014, 34, 873-883.	1.2	7
52	Introduction. Journal of Managed Care Pharmacy, 2003, 9, 2-2.	2.2	3
53	Health Economics. , 2002, , 657-671.		2